Discovery of 4′-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1093-1096

  Tellew, John E ^a,b   Baska, Rose Ann F ^a   Beyer, Sophie M ^a   Carlson, Kenneth E ^a   Cornelius, Lyndon A ^a   Fadnis, Leena ^a   Gu, Zhengxiang ^a   Kunst, Bridgette L ^a   Kowala, Mark C ^a   Monshizadegan, Hossain ^a   Murugesan, Natesan ^a   Ryan, Carol S ^a   Valentine, Maria T ^a   Yang, Yifan ^a   Macor, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BMS 248360; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; LOSARTAN; SULFAMIDE DERIVATIVE; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; BIPHENYL DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENDOTHELIN A RECEPTOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; HEART FAILURE; HYPERTENSION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; BLOOD PRESSURE; CELL STRAIN CACO 2; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; MALE; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; BINDING SITES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CACO-2 CELLS; DRUG DESIGN; HUMANS; IMIDAZOLES; INDICATORS AND REAGENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0037463780     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00018-0     Document Type: Article

References (23)

1. (a) Burnier M. Circulation. 103:2001;904.
2. (b) Ashton W.T. Exp. Opin. Invest. Drugs. 3:1994;1105.
3. (a) Elliott J.D., Ohlstein E.H., Peishoff C.E., Ellens H.M., Lago M.A. Pharm. Biotechnol. 11:1998;113.
4. (b) Spieker L.E., Noll G., Ruschitzka F.T., Luscher T.F. J. Am. Coll. Cardiol. 37:2001;1493.
5. (c) Dao H.H., Moreau P. Expert Opin. Invest. Drugs. 10:2001;1937.
6. Workers at Merck have reported on a series of phenylacetic acid derivatives with dual endothelin/angiotensin II receptor antagonist activity: Walsh T.F., Fitch K.J., Williams D.L. Jr., Murphy K.L., Nolan N.A., Pettibone D.J., Chang R.S.L., O'Malley S.S., Clineschmidt B.V., Veber D.F., Greenlee W.J. Bioorg. Med. Chem. Lett. 5:1995;1155.
7. Murugesan N., Tellew J.E., Gu Z., Kunst B.L., Fadnis L., Cornelius L.A., Baska R.A.F., Beyer S.M., Monshizadegan H., Dickinson K., Panchal B., Valentine M.T., Chong S., Morrison R.A., Carlson K.E., Powell J.R., Moreland S., Barrish J.C., Kowala M.C., Macor J.E. J. Med. Chem. 45:2002;3829.
8. Murugesan N., Gu Z., Stein P.D., Bisaha S., Spergel S., Girotra R., Lee V.G., Lloyd J., Misra R.N., Schmidt J., Mathur A., Stratton L., Kelly Y.F., Bird E., Waldron T., Liu E.C.-K., Zhang R., Lee H., Serafino R., Abboa-Offei B., Mathers P., Giancarli M., Seymour A.A., Webb M.L., Moreland S., Barrish J.C., Hunt J.T. J. Med. Chem. 41:1998;5198.
9. Carini D.J., Duncia J.V., Aldrich P.E., Chiu A.T., Johnson A.L., Pierce M.E., Price W.A., Santella J.B. III, Wells G.J., Wexler R.R., Wong P.C., Yoo S.-E., Timmermans P.B.M.W.M. J. Med. Chem. 34:1991;2525.
10. Wexler R.R., Greenlee W.J., Irvin J.D., Goldberg M.R., Prendergast K., Smith R.D., Timmermans P.B.M.W.M. J. Med. Chem. 39:1996;625.
11. Webb M.L., Meek T.D. Med. Res. Rev. 17:1997;17.
12. (a) Stein P.D., Hunt J.T., Floyd D.M., Moreland S., Dickenson K.E.J., Mitchell C., Liu E.C.-K., Webb M.L., Murugesan N., Dickey J., McMullen D., Zhang R., Lee V.G., Serafino R., Delaney C., Schaeffer T.R., Kozlowski M. J. Med. Chem. 37:1994;329.
13. (b) Stein P.D., Floyd D.M., Bisaha S., Dickey J., Girotra R., Gougoutas J.Z., Kozlowski M., Lee V.G., Liu E.C.-K., Malley M.F., McMullen D., Mitchell C., Moreland S., Murugesan N., Serafino R., Webb M.L., Zhang R., Hunt J.T. J. Med. Chem. 38:1995;1344.
14. (a) Santella J.B. III, Duncia J.V., Ensinger C.L., VanAtten M.K., Carini D.J., Wexler R.R., Chiu A.T., Wong P.C., Timmermans P.B.M.W.M. Bioorg. Med. Chem. Lett. 4:1994;2235.
15. (b) Yanagisawa H., Amemiya Y., Kanazaki T., Shimoji Y., Fujimoto K., Kitahara Y., Sada T., Mizuno M., Ikeda M., Miyamoto S., Furukawa Y., Koike H. J. Med. Chem. 39:1996;323.
16. (c) Deprez P., Guillaume J., Becker R., Corbier A., Didierlaurent S., Fortin M., Frechet D., Hamon G., Heckmann B., Heitsch H., Kleeman H.-W., Vevert J.-P., Vincent J.-C., Wagner A., Zhang J. J. Med. Chem. 38:1995;2357.
17. Murugesan, N.; Barrish, J. C.; Gu, Z.; Morrison, R. A. PCT International Application WO 98/33780, 1998.
18. (a) Watson S.P. Synth. Commun. 22:1992;2971.
19. (b) Carini, D. J. PCT International Application WO 92/00977, 1992.
20. (c) Paul R., Brockman J.A., Hallett W.A., Hanifin J.W., Tarrant M.E., Torley L.W., Callahan F.M., Fabio P.F., Johnson B.D., Lenhard R.H., Schaub R.E., Wissner A. J. Med. Chem. 28:1985;1704.
21. (d) Yanagisawa T., Ueyama N., Kawai T., Sonegawa M., Baba H., Mochizuki S., Kozakai K., Tomiyama T. Bioorg. Med. Chem. Lett. 3:1993;1559.
22. i value is the mean of at least three individual experiments.
23. A receptor antagonists such as BMS-193884 are inactive in this assay.